IOVANCE BIOTHERAPEUTICS, INC.
For the period ended Oct 29, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 29, 2026 · Filed Oct 29, 2026
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 29, 2026
IOVANCE BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | |
|---|---|
| (State of Incorporation) | |
| 001-36860 | 75-3254381 |
| Commission File Number | (I.R.S. Employer Identification No.) |
| 300 Rouse Blvd. | |
| Philadelphia, Pennsylvania | 19112 |
| (Address of Principal Executive Offices) | (Zip Code) |
| (650) 260-7120 | |
| (Registrant’s Telephone Number, Including Area Code) | |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock, par value $0.000041666 per share | IOVA | The Nasdaq Stock Market, LLC |
| Item 8.01 | Other Events. |
|---|
On October 29, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing updated results from Cohorts 1 and 2 of the Company’s Phase 2 IOV-LUN-202 trial and a biomarker-enriched precision tumor infiltrating lymphocyte strategy for lifileucel in previously treated non-squamous metastatic non-small-cell lung cancer. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
|---|
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press Release of Iovance Biotherapeutics, Inc., dated October 29, 2026 |
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 29, 2026 | Iovance Biotherapeutics, Inc. | ||
|---|---|---|---|
| By: | /s/ Frederick G. Vogt | ||
| Name: | Frederick G. Vogt, Ph.D., J.D. | ||
| Title: | Interim CEO and President, and General Counsel | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.